@Sausagerolex Posting this here for you and anyone else. It's from NICE Sept 2022, menopause/HRT/ prescribing.
Vaginal use of Utrogestan is fine. It's not licensed as such in the UK but that's an anomaly. In France and the rest of Europe, it is. (A friend of mine posted the French formulary directions on another forum. It says it can be used orally or vaginally [in women who want to avoid side effects].)
I've used Utrogestan for 9 years under a top menopause gynaecologist, who prefers women to use it vaginally, if they want to. (They are also a highly ranked fertility expert who has prescribed it for that.) FWIW it can also be used anally as a suppository I was told! The BMS does cover this topic in their report last year on the use of progesterone, where it says women can use it vaginally in individual circumstances.
The 3-month regime is here in the NICE prescribing guidance.
Regimen
The hormone replacement therapy (HRT) regimen used depends on whether the woman is perimenopausal, postmenopausal, the route of administration, and the woman's wishes.
Combined HRT can be prescribed as a:
Monthly cyclical regimen — oestrogen is taken daily and progestogen is given at the end of the cycle for 10–14 days, depending on the type of progestogen. The suggested dose of progestogen given in a continuous combined HRT regimen is a minimum of 0.5 mg/day of norethisterone or 2.5 mg/day of medroxyprogesterone acetate.
For low-dose sequential regimens norethisterone a minimum of 1mg/day given for 10 days a month, oral micronised progesterone 200 mg/day for 12 days a month, medroxyprogesterone acetate 10 mg/day for 10–14 days a month or dydrogesterone 10 mg/day for 14 days a month are suitable options.
Three-monthly cyclical regimen — oestrogen is taken daily and progestogen is given for 14 days every 13 weeks.
Continuous combined regimen — oestrogen and progestogen are taken daily.
For perimenopausal women, monthly or 3-monthly cyclical regimens may be used.
A 3-monthly regimen may be more suitable for women with infrequent periods or who are intolerant to progestogens. See the section on adverse effects for more information.
A monthly regimen produces monthly bleeding whilst a 3-monthly regimen produces a bleed every 3 months.
A continuous combined regimen is not suitable for use in the perimenopause or within 12 months of the last menstrual period.
Note: the absence of bleeding whilst taking a cyclical regimen reflects an atrophic endometrium.
Exclude pregnancy in perimenopausal women or women with premature ovarian insufficiency.
Check compliance with therapy if the progestogen component is taken separately.
If HRT was initiated in the perimenopause, consideration should be given to switching from monthly or 3-monthly cyclical regimens to continuous combined regimens after the woman becomes postmenopausal.
For postmenopausal women, monthly or 3-monthly cyclical regimens, or a continuous combined regimen may be used.
A continuous combined regimen may be preferred as it does not produce withdrawal bleeding.
Note: a continuous combined regimen may produce irregular bleeding or spotting for the first 4–6 months of treatment. If bleeding persists beyond 6 months, becomes heavier, or occurs after a spell of amenorrhoea, endometrial pathology should be excluded.